Bionano Genomics (BNGO) Stock Analysis & Winston Score

Bionano Genomics is a medical technology company that makes specialized machines and software for analyzing DNA. Its main product is the Saphyr system, which uses a technology called optical genome mapping to help scientists and doctors find genetic abnormalities — like large structural changes in chromosomes — that traditional DNA tests often miss. Its customers include research labs, hospitals, and academic medical centers studying genetic diseases and cancers. The company sells its Saphyr instruments, the consumable chips needed to run tests, and software licenses, creating a mix of one-time hardware revenue and recurring consumable sales. Bionano operates primarily in the United States but also has customers in Europe and Asia. Despite a 47% gross margin on its products, the company spends far more than it earns, running a deeply negative operating margin, which means it is burning through cash. The key risk is whether Bionano can grow adoption of optical genome mapping fast enough to reach profitability before needing to raise additional capital.